课题基金 / 基金详情

项目摘要

项目成果

Frederick M Ausubel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This proposal describes experiments designed to identify and characterize Caenorhabditis elegans innate immune signaling pathways. During the past several years, my laboratory has pioneered the development of C. elegans pathogenicity models based on the observation that a remarkably large number of human pathogenic bacteria and yeasts kill C. elegans. Each of these pathogens has been studied by simply replacing C. elegans' normal food source (a lawn of Escherichia coli strain OP50) with a pathogen, and monitoring the survival of the nematodes overtime. This simple feeding-based pathogenicity model coupled with powerful genetic and genomic technologies, including RNAi feeding libraries, makes C. elegans an attractive model in which to dissect immune response signaling pathways. We have established that the C. elegans response to pathogen attack involves a conserved p38 MARK signaling pathway, a Toll-lnterleukin 1 Receptor (TIR)-domain-containing signaling component, programmed cell death, and antimicrobial effector proteins, all of which also function in mammalian innate immunity. Using both forward and reverse genetic approaches, we have identified at least six C. elegans genes (tir-1, nsy-1, sek-1, mek-1, vhp-1 and pmk-1) that function in a MARK innate immune signaling pathway homologous to the p38 MARK signaling pathway that functions in the mammalian innate immune response. We have also shown that the DAF-2 insulin-like signaling pathway plays a role in innate immune signaling. In preliminary data we have identified a variety of new genes that appear to encode additional components of the C. elegans PMK-1 (p38) signaling pathway as well as components of other immune pathways. We have also demonstrated that resistance to pathogenmediated killing can be independent of overall worm longevity. The specific aims are designed to further elucidate the role of the PMK-1 (p38) signaling pathway and other signaling pathways in activating the C. elegans immune response and to delineate the relationship between longevity and pathogen resistance.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
First-in-class small molecule therapeutics to enhance gut barrier function in inflammatory bowel disease
  • 批准号:
    10251430
  • 项目类别:
  • 资助金额:
    $25.12万
  • 财政年份:
    2021
  • 负责人:
    Frederick M Ausubel
  • 依托单位:
First-in-class small molecules that enhance lung barrier function during acute respiratory distress syndrome (ARDS) as potential therapeutics for COVID-19
  • 批准号:
    10254996
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    2021
  • 负责人:
    Frederick M Ausubel
  • 依托单位:
Discovering Novel Therapeutics for Myotonic Dystrophy Type 1 (DM1)
  • 批准号:
    9409067
  • 项目类别:
  • 资助金额:
    $15.0万
  • 财政年份:
    2017
  • 负责人:
    Frederick M Ausubel
  • 依托单位:
Identifying novel anti-infectives by high through-put screening in whole animals
  • 批准号:
    7764005
  • 项目类别:
  • 资助金额:
    $84.17万
  • 财政年份:
    2009
  • 负责人:
    Frederick M Ausubel
  • 依托单位:
国内基金
海外基金
犬钩虫中Caenorhabditis elegans daf同源基因的鉴定和功能研究
  • 批准号:
    30972181
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2009
  • 负责人:
    杨玉荣
  • 依托单位:
利用线虫(Caenorhabditis elegans)模型研究14-3-3蛋白在机体抵御逆境因子胁迫过程中的分子作用机制
  • 批准号:
    30771234
  • 项目类别:
    面上项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2007
  • 负责人:
    王亚梅
  • 依托单位: